Labcorp is a Full Service Laboratory for Suboxone® Providers

In an effort to address the opioid crisis, Labcorp has developed several test options to help manage Suboxone® medication-assisted treatment (MAT) for opioid-dependent patients.

Labcorp offers individual and profile test options, including medication-assisted treatment monitoring profiles. Learn more about our MAT profiles and clinical testing to support the care of your patients.

Features of all MAT drug test options:

  • Buprenorphine results listed at top of report
  • Detection thresholds optimized for patients in MAT
  • Samples retained for at least four weeks to allow for additional testing
  • Buprenorphine, norbuprenorphine, and THC definitive results normalized for creatinine concentration, allowing direct comparison over time
  • Detection of naloxone in definitive tests for buprenorphine
  • All reports display our provider reference hotline for clinical consultation

For more information, please contact our clinical drug testing support line: 877-474-5767.

Learn more about our MAT profiles

View Webinar: Medication-Assisted Treatment (MAT) - Clinical Drug Testing Overview

Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to treat opioid use disorder (OUD). Treatment professionals agree that monitoring drug use during MAT can be a powerful incentive for abstinence, and it can also help identify OUD relapse.

Clinical drug testing is an important tool in managing patients who are receiving MAT. During this webinar, our toxicology experts reviewed Labcorp’s MAT portfolio and provided answers to questions that can help you leverage our differentiated services to their full potential.

This webinar includes:

  • An overview of MAT and the importance of clinical drug testing
  • Drug testing trends within the MAT population
  • The clinical value of advanced specimen validity testing
  • Review of specialized MAT testing options and the unique components designed to help you manage patients receiving treatment with Suboxone®/buprenorphine
  • Live Q&A with the presenters

 

Presenters

Hemamalini Ketha, PhD, NRCC, SC (ASCP), FAACC Discipline Director, Clinical Toxicology

Hemamalini Ketha, PhD, NRCC, SC (ASCP), FAACC

Discipline Director, Clinical Toxicology

Karla J. Walker, PharmD, DABCC, FAACC Discipline Director, Clinical Toxicology

Karla J. Walker, PharmD, DABCC, FAACC

Discipline Director, Clinical Toxicology